Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR57667B in early Parkinson's Disease
NCT00220272Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of xaliproden in Parkinson's disease (PD), sponsored by Sanofi. Started Jan 2004; status: completed.
02
Drugs
xaliproden
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00220272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00220272.